Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) shares traded up 13.1% on Wednesday . The stock traded as high as C$3.56 and last traded at C$3.45. 5,663 shares were traded during trading, a decline of 24% from the average session volume of 7,410 shares. The stock had previously closed at C$3.05.
Eupraxia Pharmaceuticals Stock Performance
The business’s 50 day moving average is C$2.80 and its two-hundred day moving average is C$2.72.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- Financial Services Stocks Investing
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Stock Splits, Do They Really Impact Investors?
- 3 Penny Stocks Ready to Break Out in 2025
- 3 Warren Buffett Stocks to Buy Now
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
